Revised SPC: Vipdomet 12.5 mg/1000 mg (alogliptin/metformin) film coated tablets

SPC updated to warn that there have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including alogliptin. If bullous pemphigoid is suspected, alogliptin should be discontinued. Also interstitial nephritis added as ADR of unknown frequency.

Source:

electronic Medicines compendium